Mark FitzGerald, a partner at Nixon Peabody, and members of the HGF Microbiome IP Team examine the ruling in Genome & Co. v. University of Chicago. and its impact on patents covering microbiome therapeutics in the U.S., and the HGF Microbiome IP team provides perspective regarding challenges to patents covering similar subject matter in the European Patent Office.
The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.
Intellectual Property Alert | 05.12.20
Intellectual Property Alert | 05.07.20